Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus . Positively regulates MAPK signal transduction pathway . Dephosphorylates GAB1, ARHGAP35 and EGFR . Dephosphorylates ROCK2 at ''Tyr-722'' resulting in stimulation of its RhoA binding activity . Dephosphorylates CDC73 . Dephosphorylates SOX9 on tyrosine residues, leading to inactivate SOX9 and promote ossification (By similarity). Dephosphorylates tyrosine-phosphorylated NEDD9/CAS-L . .

Tyrosine-protein phosphatase non-receptor type 11 (EC 3.1.3.48) (Protein-tyrosine phosphatase 1D) (PTP-1D) (Protein-tyrosine phosphatase 2C) (PTP-2C) (SH-PTP2) (SHP-2) (Shp2) (SH-PTP3),PTPN11 PTP2C SHPTP2

Q06124,P35235,P41499

5781/19247/25622

Human,Mouse,Rat

WB,IHC,IF,ICC,IP,ELISA

WB 1:1000-5000
IHC 1:200-1:1000
IF 1:100-1:400
ICC 1:100-1:400
IP 1:50-1:200

Phospho-SH-PTP2 (Y542) Antibody detects endogenous levels of SH-PTP2 protein only when phosphorylated at Y542.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):HEyTN

72kDa

Rabbit

Monoclonal

U282

IgG,Kappa

Protein A

PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA

Store at -20℃. Stable for 12 months from date of receipt.